Fosun's Bold Steps at CIIE: A Gateway to Global Innovation
November 8, 2024, 6:53 pm
The China International Import Expo (CIIE) is more than just an exhibition. It’s a vibrant marketplace where ideas meet opportunity. This year, Fosun International, a major player in the global healthcare landscape, showcased its innovations at the seventh CIIE in Shanghai. The event, held from November 5, 2024, to November 10, 2024, served as a stage for Fosun to highlight its commitment to innovation and globalization.
Fosun's presence at CIIE is a testament to its strategy. For seven consecutive years, the company has used this platform to unveil groundbreaking medical technologies. This year was no different. Fosun Pharma's booth dazzled visitors with cutting-edge medical devices and pharmaceuticals. Among the stars was the Ion Robotic Bronchoscopy system, a game-changer in lung cancer diagnostics. This system, which made its debut at CIIE, is a beacon of hope for patients facing a daunting diagnosis.
Lung cancer is a silent killer. In 2022, China reported over a million new cases. The survival rate is disheartening. The Ion system offers a lifeline. It enhances the precision of bronchoscopy, allowing for earlier detection. By the third quarter of 2024, over 736 Ion systems had been installed globally, with more than 150,000 procedures performed. This is not just a statistic; it’s a transformation from exhibit to product, from concept to reality.
Fosun's journey at CIIE reflects a broader narrative. The company is not merely a participant; it is a pioneer. Guo Guangchang, Fosun's Chairman, emphasized the importance of CIIE as a platform for high-level openness. Fosun has turned many exhibits into products and many exhibitors into investors. This transformation is vital for fostering innovation in China’s healthcare sector.
The CIIE has become a catalyst for change. Fosun's commitment to innovation is evident in its investment strategy. In the first half of 2024 alone, Fosun invested RMB 3.5 billion in technological advancements. This investment fuels the development of new treatments, particularly in neurological diseases. The introduction of the V2 model of the Exablate Neuro FUS system at CIIE is a prime example. This non-invasive treatment offers hope to patients with essential tremor and Parkinson's disease, conditions that have long been challenging to manage.
The partnership between Fosun and Insightec is noteworthy. Their joint venture, Fosun-Insightec, aims to enhance the lives of patients through innovative treatments. This collaboration exemplifies Fosun's approach: addressing real customer needs through innovation. It’s about creating solutions that resonate with patients and healthcare providers alike.
Fosun's vision extends beyond borders. The company is deeply rooted in China but has a global outlook. With operations in over 35 countries, Fosun is committed to connecting global markets. This commitment was further solidified through a memorandum of understanding with Standard Chartered Bank during CIIE. This strategic partnership aims to deepen cooperation in the Belt and Road markets, enhancing financial services for Fosun's global operations.
Standard Chartered's role as a "super connector" in cross-border finance complements Fosun's ambitions. The bank's extensive network will support Fosun's growth, providing comprehensive financial solutions tailored to its needs. This collaboration is a win-win, fostering innovation and globalization.
Fosun's participation in CIIE is not just about showcasing products; it’s about building a happiness ecosystem. The company aims to provide high-quality products and services to one billion customers worldwide. This ambitious goal underscores Fosun's commitment to improving lives through innovation.
At CIIE, Fosun also highlighted its achievements in cancer care. The introduction of Yi Kai Da, China’s first CAR-T cell therapy, marked a significant milestone. This therapy has transformed the treatment landscape for lymphoma patients. With over 170 treatment centers across China, Yi Kai Da is making waves in the healthcare sector. It’s a testament to Fosun’s dedication to accessibility and treatability.
The CIIE serves as a mirror reflecting the evolution of global trade and innovation. Fosun’s journey at this expo is a microcosm of the larger narrative of globalization. The company is not just adapting; it is leading. By leveraging the CIIE platform, Fosun is poised to expand its reach and influence.
As the world becomes increasingly interconnected, Fosun’s strategy of combining globalization with innovation is a roadmap for success. The company’s ability to transform exhibits into products and ideas into realities is a powerful narrative. It’s a story of resilience, ambition, and a commitment to improving lives.
In conclusion, Fosun's participation in CIIE is a bold statement. It reflects a commitment to innovation, collaboration, and global outreach. As the company continues to navigate the complexities of the global market, its journey at CIIE will undoubtedly shape the future of healthcare. Fosun is not just a player in the game; it is a game-changer. The future is bright, and the possibilities are endless.
Fosun's presence at CIIE is a testament to its strategy. For seven consecutive years, the company has used this platform to unveil groundbreaking medical technologies. This year was no different. Fosun Pharma's booth dazzled visitors with cutting-edge medical devices and pharmaceuticals. Among the stars was the Ion Robotic Bronchoscopy system, a game-changer in lung cancer diagnostics. This system, which made its debut at CIIE, is a beacon of hope for patients facing a daunting diagnosis.
Lung cancer is a silent killer. In 2022, China reported over a million new cases. The survival rate is disheartening. The Ion system offers a lifeline. It enhances the precision of bronchoscopy, allowing for earlier detection. By the third quarter of 2024, over 736 Ion systems had been installed globally, with more than 150,000 procedures performed. This is not just a statistic; it’s a transformation from exhibit to product, from concept to reality.
Fosun's journey at CIIE reflects a broader narrative. The company is not merely a participant; it is a pioneer. Guo Guangchang, Fosun's Chairman, emphasized the importance of CIIE as a platform for high-level openness. Fosun has turned many exhibits into products and many exhibitors into investors. This transformation is vital for fostering innovation in China’s healthcare sector.
The CIIE has become a catalyst for change. Fosun's commitment to innovation is evident in its investment strategy. In the first half of 2024 alone, Fosun invested RMB 3.5 billion in technological advancements. This investment fuels the development of new treatments, particularly in neurological diseases. The introduction of the V2 model of the Exablate Neuro FUS system at CIIE is a prime example. This non-invasive treatment offers hope to patients with essential tremor and Parkinson's disease, conditions that have long been challenging to manage.
The partnership between Fosun and Insightec is noteworthy. Their joint venture, Fosun-Insightec, aims to enhance the lives of patients through innovative treatments. This collaboration exemplifies Fosun's approach: addressing real customer needs through innovation. It’s about creating solutions that resonate with patients and healthcare providers alike.
Fosun's vision extends beyond borders. The company is deeply rooted in China but has a global outlook. With operations in over 35 countries, Fosun is committed to connecting global markets. This commitment was further solidified through a memorandum of understanding with Standard Chartered Bank during CIIE. This strategic partnership aims to deepen cooperation in the Belt and Road markets, enhancing financial services for Fosun's global operations.
Standard Chartered's role as a "super connector" in cross-border finance complements Fosun's ambitions. The bank's extensive network will support Fosun's growth, providing comprehensive financial solutions tailored to its needs. This collaboration is a win-win, fostering innovation and globalization.
Fosun's participation in CIIE is not just about showcasing products; it’s about building a happiness ecosystem. The company aims to provide high-quality products and services to one billion customers worldwide. This ambitious goal underscores Fosun's commitment to improving lives through innovation.
At CIIE, Fosun also highlighted its achievements in cancer care. The introduction of Yi Kai Da, China’s first CAR-T cell therapy, marked a significant milestone. This therapy has transformed the treatment landscape for lymphoma patients. With over 170 treatment centers across China, Yi Kai Da is making waves in the healthcare sector. It’s a testament to Fosun’s dedication to accessibility and treatability.
The CIIE serves as a mirror reflecting the evolution of global trade and innovation. Fosun’s journey at this expo is a microcosm of the larger narrative of globalization. The company is not just adapting; it is leading. By leveraging the CIIE platform, Fosun is poised to expand its reach and influence.
As the world becomes increasingly interconnected, Fosun’s strategy of combining globalization with innovation is a roadmap for success. The company’s ability to transform exhibits into products and ideas into realities is a powerful narrative. It’s a story of resilience, ambition, and a commitment to improving lives.
In conclusion, Fosun's participation in CIIE is a bold statement. It reflects a commitment to innovation, collaboration, and global outreach. As the company continues to navigate the complexities of the global market, its journey at CIIE will undoubtedly shape the future of healthcare. Fosun is not just a player in the game; it is a game-changer. The future is bright, and the possibilities are endless.